A Multi-center Clinical Study of Zanubrutinib in Combination With First-line Chemoimmunotherapy in Patients With Grade 3A High-risk Follicular Lymphoma
Latest Information Update: 25 Dec 2024
Price :
$35 *
At a glance
- Drugs Zanubrutinib (Primary)
- Indications Follicular lymphoma
- Focus Therapeutic Use
- Acronyms ZCM3AHRFL
- 25 Dec 2024 New trial record